FernandoDangondMD

PubMed

• 1 citations
  Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
  Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie ...> ;Neurology and Therapy. 2024 Apr 1
• Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
  Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Fernando Dangond, Dominic Jack, Patrick Vermersch> ;Neurodegenerative Disease Management. 2022 Dec 1
• The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
  Patrick Vermersch, Andrew Galazka, Fernando Dangond, Doris Damian, Schiffon L Wong, Dominic Jack, Gerard Harty> ;Neurodegenerative Disease Management. 2022 Dec 1
• Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
  Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist, Patricia K Coyle, Fernando Dangond, Nektaria Alexandri, Andrew Galazka> ;Neurodegenerative Disease Management. 2022 Dec 1
• 6 citations
  Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
  Orestis Papasouliotis, David Mitchell, Pascal Girard, Fernando Dangond, Martin Dyroff> ;Clinical and Translational Science. 2022 Dec 1
• 2 citations
  Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
  Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas P Leist> ;Neurodegenerative Disease Management. 2022 Feb 1
• 96 citations
  Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phas...
  Andre C. Kalil, Aneesh K. Mehta, Thomas F Patterson, Nathaniel B. Erdmann, Carlos A. Gomez, Mamta K. Jain, Cameron R. Wolfe, Guillermo M. Ruiz-Palacios, Susan Kline, J...> ;The Lancet. Respiratory Medicine. 2021 Oct 18
• 4 citations
  Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
  Mark S. Freedman, Jérôme Wojcik, Kristina H. Holmberg, Markus Fluck, Mauro D'Antonio, Yann Hyvert, Sofia Stinchi, Vittorio D'Urso, Fernando Dangond> ;Journal of Neuroimmunology. 2021 Nov 15
• 15 citations
  Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An...
  Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Fernando Dangond, B. Keller, Dominic Jack, Patrick Vermersch> ;Advances in Therapy. 2021 Aug 9
• 5 citations
  Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis:
  Jiwon Oh, Bryan Walker, Gavin Giovannoni, Dominic Jack, Fernando Dangond, Axel Nolting, Julie Aldridge, Lori A Lebson, Thomas Leist> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021 Jul 13
• 14 citations
  Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
  Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas Leist, Patricia K. Coyle, Fernando Dangond, B. Keller, Nektaria Alexandri, Andrew Galazka> ;Multiple Sclerosis. 2021 May 10
• 4 citations
  Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
  Bruce A.C. Cree, James D. Bowen, Hans-Peter Hartung, Patrick Vermersch, Bruce Hughes, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Megan Grosso, Daniel...> ;Multiple Sclerosis and Related Disorders. 2021 Apr 1
• 3 citations
  Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
  Mark S. Freedman, Patricia K. Coyle, Giancarlo Comi, Susan Scarberry, Doris Damian, Yann Hyvert, Fernando Dangond, Andrew Galazka, Dominic Jack, Lori A Lebson, Thomas ...> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2021 Feb 24
• 17 citations
  Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.
  Fernando Dangond, Alexis Donnelly, Reinhard Hohlfeld, Catherine Lubetzki, Susan Kohlhaas, Letizia Leocani, Olga Ciccarelli, Bruno Stankoff, Maria Pia Sormani, Jeremy C...> ;Nature Reviews. Neurology. 2021 Jan 22
• 8 citations
  Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modif...
  Patrick Vermersch, Andrew Galazka, Fernando Dangond, Doris Damian, Schiffon L. Wong, Dominic Jack, Gerard Harty> ;Current Medical Research and Opinion. 2021 Feb 1
• 34 citations
  The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
  Kottil Rammohan, Patricia K. Coyle, Elke Sylvester, Andrew Galazka, Fernando Dangond, Megan Grosso, Thomas Leist> ;Drugs. 2020 Dec 1
• 16 citations
  Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
  Gavin Giovannoni, Andrew Galazka, Regina Schick, Thomas Leist, Giancarlo Comi, Xavier Montalban, Doris Damian, Fernando Dangond, Stuart D. Cook> ;Drug Safety. 2020 Jul 1
• 4 citations
  Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
  Mark S. Freedman, Staley A. Brod, Barry A Singer, Bruce A. Cohen, Brooke Hayward, Fernando Dangond, Patricia K. Coyle> ;Journal of Neurology. 2020 Jan 1
• 2 citations
  Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
  Robert Hermann, Jeffrey S. Litwin, Lena E. Friberg, Fernando Dangond, Alain Munafo> ;British Journal of Clinical Pharmacology. 2019 Jul 1
• 76 citations
  Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers:
  Olaf Stüve, Per Soelberg Soerensen, Thomas Leist, Gavin Giovannoni, Yann Hyvert, Doris Damian, Fernando Dangond, Ursula Boschert> ;Therapeutic Advances in Neurological Disorders. 2019 Jun 18
• 176 citations
  Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
  Xavier Montalban, Douglas L. Arnold, Martin S. Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Jonathan Willmer, Emily Martin, Fernando Dangond, Sana Syed, Jerry S...> ;The New England Journal of Medicine. 2019 May 10
• 39 citations
  Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study:
  Gavin Giovannoni, Per Soelberg Sørensen, Stuart D. Cook, Kottil Rammohan, Peter Rieckmann, Giancarlo Comi, Fernando Dangond, Christine Hicking, Patrick Vermersch> ;Multiple Sclerosis. 2019 May 1
• 78 citations
  Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
  Giancarlo Comi, Stuart D. Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Andrew Galazka, Axel Nolting, Christine Hicking, Fernando ...> ;Multiple Sclerosis and Related Disorders. 2019 Apr 1
• 8 citations
  Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in P...
  Nadia Terranova, Christine Hicking, Fernando Dangond, Alain Munafo> ;Clinical Pharmacokinetics. 2019 Mar 1
• 12 citations
  Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis
  Patrick Vermersch, Vittorio Martinelli, Claudia Christina Pfleger, Peter Rieckmann, Lucia Alonso-Magdalena, Andrew Galazka, Fernando Dangond, Lawrence D. Phillips> ;Clinical Therapeutics. 2019 Feb 1
• Join now to see all